Yüklüyor......
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?
Despite recent advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC), agents that provide durable disease control and long-term survival are still needed. It is a fact that a tumor-induced immunosuppressive status (mediated by aberrant activation of inhibitory immune c...
Kaydedildi:
| Yayımlandı: | Oncol Rev |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
PAGEPress Publications, Pavia, Italy
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4943092/ https://ncbi.nlm.nih.gov/pubmed/27471580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/oncol.2016.293 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|